ATE542537T1 - Verbindungen auf mangan- und eisenbasis für die elastogenese und behandlung von bindegewebe - Google Patents

Verbindungen auf mangan- und eisenbasis für die elastogenese und behandlung von bindegewebe

Info

Publication number
ATE542537T1
ATE542537T1 AT05723320T AT05723320T ATE542537T1 AT E542537 T1 ATE542537 T1 AT E542537T1 AT 05723320 T AT05723320 T AT 05723320T AT 05723320 T AT05723320 T AT 05723320T AT E542537 T1 ATE542537 T1 AT E542537T1
Authority
AT
Austria
Prior art keywords
elastogenesis
treatment
present
connective tissue
describes
Prior art date
Application number
AT05723320T
Other languages
English (en)
Inventor
Thomas Mitts
Aleksander Hinek
Severa Bunda
Felipe Jimenez
Original Assignee
Human Matrix Sciences Llc
Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Matrix Sciences Llc, Univ Toronto filed Critical Human Matrix Sciences Llc
Application granted granted Critical
Publication of ATE542537T1 publication Critical patent/ATE542537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05723320T 2004-02-20 2005-02-22 Verbindungen auf mangan- und eisenbasis für die elastogenese und behandlung von bindegewebe ATE542537T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54668204P 2004-02-20 2004-02-20
US62210404P 2004-10-26 2004-10-26
PCT/US2005/005281 WO2005082386A2 (en) 2004-02-20 2005-02-22 Manganese and iron based compounds for elastogenesis and connective tissue treatment

Publications (1)

Publication Number Publication Date
ATE542537T1 true ATE542537T1 (de) 2012-02-15

Family

ID=34915581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723320T ATE542537T1 (de) 2004-02-20 2005-02-22 Verbindungen auf mangan- und eisenbasis für die elastogenese und behandlung von bindegewebe

Country Status (5)

Country Link
US (2) US7666829B2 (de)
EP (1) EP1725245B1 (de)
AT (1) ATE542537T1 (de)
CA (2) CA2562871C (de)
WO (1) WO2005082386A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073616A2 (en) 2003-02-14 2004-09-02 Human Matrix Sciences Llc Elastin digest compositions and methods utilizing same
US7803522B2 (en) * 2004-02-13 2010-09-28 Human Matrix Sciences, Llc Elastin producing fibroblast formulations and methods of using the same
WO2005118783A1 (en) * 2004-05-28 2005-12-15 Human Matrix Sciences, Llc Prognostic tests for development of dermal stretch marks and implications for the preventive treatment thereof
DE602005015475D1 (de) * 2004-11-09 2009-08-27 Cupron Corp Verfahren und materialien für die hautpflege
US8114829B2 (en) * 2005-02-22 2012-02-14 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US7566693B2 (en) * 2005-02-22 2009-07-28 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
US8642578B2 (en) 2005-03-29 2014-02-04 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same
CA2605078C (en) * 2005-04-15 2013-01-08 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
CA2608747C (en) 2005-05-17 2013-01-22 Human Matrix Sciences, Llc Elastin producing fibroblast formulations and methods of using the same
US20080138472A1 (en) * 2006-12-12 2008-06-12 Delse Alexandre High fiber rotary molded cookies containing inulin and resistant starch
WO2008100789A2 (en) 2007-02-16 2008-08-21 Benaroya Research Institute At Virginia Mason Compositions and methods for altering elastogenesis
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US8623335B2 (en) * 2007-09-10 2014-01-07 Tauna Ann Waddington Scar and rosacea and other skin care treatment composition and method
GB2456528B (en) * 2008-01-16 2012-08-22 Pangaea Lab Ltd Antioxidant for use in cosmetic, medicated and pharmaceutical compositions
FR2957252B1 (fr) * 2010-03-09 2016-04-08 Lvmh Rech Composition cosmetique
US20120116346A1 (en) * 2010-11-05 2012-05-10 Mitts Thomas F Hyperthermia induced deposition of elastin fibers
US9387194B2 (en) 2012-01-18 2016-07-12 Human Matrix Sciences, Llc Sodium ascorbate stimulation of elastogenesis
US10842913B2 (en) 2012-12-10 2020-11-24 Allergan Pharmaceuticals International Limited Scalable three-dimensional elastic construct manufacturing
RU2677637C2 (ru) 2013-08-13 2019-01-18 Эластаджен Пти Лтд Регенерация поврежденной ткани
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
CN107405305B (zh) * 2015-01-20 2020-12-25 泰特拉德姆集团有限责任公司 提供粘膜和皮肤屏障恢复的通用局部药物递送载体和多因子组织保湿剂
BR112019008509A2 (pt) * 2016-11-04 2019-07-09 Allergan Pharmaceuticals Int Ltd dispositivos biossintéticos
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
CN109770203A (zh) * 2019-03-08 2019-05-21 天津保元堂生物科技有限公司 一种植物益生元柠檬酸铁胺的复合配方及其制备方法
FR3107186B1 (fr) * 2020-02-19 2022-08-26 Claire Bianchin Nouvelle composition cosmetique et/ou dermatologique a synergie osmotique et procede de fabrication afferent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7302M (de) * 1966-03-04 1969-09-29
US4173453A (en) * 1976-04-09 1979-11-06 CDC Research Inc. Topical hair coloring formulation in the form of suspension, lotion and cream
US4259318A (en) * 1978-03-02 1981-03-31 University Of Houston, Central Campus Poison ivy relief composition
US4806344A (en) * 1987-01-05 1989-02-21 Gaskin Frances C Sun protectant composition and method
DE3929411A1 (de) 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
NL194959C (nl) * 1988-10-04 2003-09-02 Otsuka Pharma Co Ltd Preparaat voor het toedienen van ijzer.
EP0799018A4 (de) * 1994-12-21 2000-03-29 Cosmederm Technologies Formulierungen und verfahren zur verminderung von hautirritationen
US6475501B1 (en) 1997-06-04 2002-11-05 The Procter & Gamble Company Antiviral compositions for tissue paper
US6069129A (en) * 1998-03-13 2000-05-30 Mrs, Llc Elastin derived composition and method of using same
US6645948B2 (en) * 1998-03-24 2003-11-11 George D. Petito Nutritional composition for the treatment of connective tissue
US6117435A (en) * 1998-06-24 2000-09-12 Color Access, Inc. Natural look cosmetic compositions
US6333039B1 (en) * 1998-09-25 2001-12-25 Gojo Industries, Inc. Opaque skin sanitizing composition
US6444647B1 (en) * 1999-04-19 2002-09-03 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
FR2809005B1 (fr) 2000-05-18 2002-12-27 Oreal Utilisation du manganese dans le traitement des rides
US20020002854A1 (en) * 2000-07-05 2002-01-10 Yuzo Imoto Vehicle passenger distinguishment system with sensor cells installed inside seat
DE10043466A1 (de) * 2000-09-04 2002-03-28 Johannes Wohlrab Manganverbindungen enthaltende Zubereitung zur topischen Applikation und deren Verwendungen
US20030026872A1 (en) * 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
GB2376886A (en) * 2001-06-27 2002-12-31 Johnson & Johnson Medical Ltd Treatment and prevention of lipodermatosclerosis
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
WO2004073616A2 (en) * 2003-02-14 2004-09-02 Human Matrix Sciences Llc Elastin digest compositions and methods utilizing same
US7803522B2 (en) * 2004-02-13 2010-09-28 Human Matrix Sciences, Llc Elastin producing fibroblast formulations and methods of using the same
US7566693B2 (en) * 2005-02-22 2009-07-28 Human Matrix Sciences, Llc Elastin protective polyphenolics and methods of using the same

Also Published As

Publication number Publication date
US20050208150A1 (en) 2005-09-22
CA2846382A1 (en) 2005-09-09
US7666829B2 (en) 2010-02-23
WO2005082386A3 (en) 2006-04-06
US9006170B2 (en) 2015-04-14
CA2562871A1 (en) 2005-09-09
WO2005082386A2 (en) 2005-09-09
EP1725245A2 (de) 2006-11-29
CA2846382C (en) 2017-09-19
CA2562871C (en) 2014-06-10
EP1725245B1 (de) 2012-01-25
US20100247454A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
WO2005082386A3 (en) Manganese and iron based compounds for elastogenesis and connective tissue treatment
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
EP2006298A3 (de) Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon
MX2010004074A (es) Combinacion 059.
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
HRP20120887T1 (en) Adherent cells from adipose or placenta tissues and use thereof in therapy
ATE523221T1 (de) Systeme und verfahren für die bilaterale stimulierung von linken und rechten ästen der dorsalen genitalnerven zur behandlung von funktionsstörungen, wie z.b. harninkontinenz
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
EP2298861A3 (de) Mesenchymale Stammzellen und deren Verwendungen
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
UA95902C2 (ru) Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
WO2005076979A3 (en) Diagnosis and therapeutics for cancer
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
WO2010093993A3 (en) Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
DE602007012107D1 (de) Kosmetische oder dermatologische zubereitungen mit n-acetylcystein
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
GB0416508D0 (en) Therapeutic agents
DE60315842D1 (de) Verwendung von hesperidin oder einem seiner derivate zur herstellung eines medikaments für die stimulierung der knochenbildung
CA2534577A1 (en) Method for promoting bone growth
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
PL1715890T3 (pl) CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
DE602005013788D1 (de) ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung